The therapeutic purpose of Фторотан (Halothane) is used as a general anesthetic to help manage symptoms related to loss of awareness during medical procedures. It is commonly used for both the entry into and the sustained maintenance of surgical anesthesia in adults and children.

Фторотан is applied across clinical settings where temporary symptom management is appropriate, including the induction and maintenance of general anesthesia, managing airway reactivity, which provides supportive benefit for stable breathing, and in specific contexts involving heightened organ-specific functional stress. This provides supportive relief by helping to manage symptoms that interfere with daily comfort. The agent is considered relevant for its use in specific patient groups, particularly children and infants requiring inhalational induction, due to its ability to provide a non-pungent experience.

“This benefit assists with maintaining functional stability during the procedure.”

This contributes to easing the overall symptom load by supporting the clinical need for loss of awareness, suppression of reflexes, and relief from bronchial constriction during interventions.

Quick Fact: Relief for Symptoms related to heightened physiological activity and Airway Constriction

Regulatory References

1. World Health Organization Essential Medicines List

The use of Фторотан (Halothane) is strictly defined by official regulatory criteria, primarily based on patient history and pre-existing conditions. These rules determine who is eligible to receive this general anesthetic and who is formally excluded.

Absolute Contraindications

Exclusion Group	Regulatory Basis
History of Liver Reaction	Prior unexplained jaundice, fever (pyrexia), or severe hepatic dysfunction following exposure to Halothane or other halogenated agents.
Genetic Susceptibility	Known or suspected genetic predisposition to Malignant Hyperthermia (MH).

Eligibility Restrictions and Caution

• Age Groups: Use in pediatric patients is common, but dosage must be individually determined. Reduced concentrations are typically needed for older adults. Children under 18 undergoing dental procedures outside a hospital setting are often excluded.
• Reproductive Status: Use during pregnancy is generally not recommended, particularly in early gestation, as safe use regarding fetal development is not established. It is also not recommended for obstetrical anesthesia unless specific uterine relaxation is required.
• Comorbidities: Special caution is required for patients with pre-existing liver disease, renal failure, and markedly raised intracranial pressure (where use must be preceded by pressure-reducing measures). Patients with previous exposure followed by unexplained jaundice must use alternative agents.

Interactions with other medicines and products

The official regulatory profile for Фторотан (Halothane) documents several clinically significant interactions that require specific procedural constraints during co-administration.

Documented Interacting Medicinal Products

The primary focus of the interaction profile is managing risks associated with two therapeutic classes, as mandated by regulatory authorities like the FDA and EMA:

• Adrenergic/Sympathomimetic Agents: Concurrent use, particularly with adrenaline (epinephrine) for local infiltration, significantly increases the risk of ventricular arrhythmias due to the drug's effect of sensitizing the myocardium. Official labeling mandates strict limitations on the concentration and total dose of epinephrine administered (e.g., maximum 10 mu g per two minutes or 30 mu g per hour) to mitigate this cardiac risk.

• Neuromuscular Blocking Agents: Фторотан potentiates the effects of non-depolarizing and depolarizing muscle relaxants (e.g., tubocurarine). This interaction requires a mandatory reduction in the dosage of the neuromuscular blocking agent to prevent excessive or prolonged muscle paralysis.

Other Interactions and Procedural Constraints

Other documented interactions include those with tricyclic antidepressants, which also increase the likelihood of cardiac dysrhythmias. The use of aminoglycoside antibiotics may result in enhanced neuromuscular depression. Additionally, aminophylline and theophylline are noted as interacting substances associated with potential cardiac rhythm disturbances. The interaction profile serves to document these mandatory clinical constraints and dose restrictions necessary for safe co-administration during medical procedures.

How Фторотан Works

Фторотан exerts its pharmacodynamic effects primarily through two mechanistic domains: central nervous system (CNS) depression and direct cardiovascular modulation.

In the CNS, the drug acts as a positive allosteric modulator on inhibitory GABAA and Glycine receptors while simultaneously functioning as an antagonist at excitatory NMDA and neuronal nicotinic Acetylcholine receptors (nAChRs). This dual-action mechanism significantly shifts the balance of neurotransmission towards inhibition, causing a global, profound suppression of nerve activity across the brain and spinal cord, resulting in deep depression of cortical function. This enhanced inhibitory signaling at the spinal level also reduces efferent motor signal transmission, leading to a reduction of skeletal muscle tone.

Peripherally, the drug directly influences myocardial function by modulating voltage-gated ion channels, specifically those regulating Ca^2+ and K^+ flow in heart muscle cells. This action leads to a dose-dependent reduction in myocardial contractility and an increase in the heart's sensitivity to circulating catecholamines.

Administration Scope: Delivery Method and Setting

Фторотан (Halothane) is administered solely via the inhalation route as a vaporized liquid. Its application is strictly confined to controlled clinical environments and requires the use of a calibrated vaporizer specifically designed for the agent to ensure accurate and reliable delivery. This specialized context mandates that administration occurs under the continuous supervision of experienced clinicians with immediate access to necessary resuscitation facilities.

Dosing by Concentration and Titration

The dosage is defined not by weight or volume, but as a percentage concentration (% v/v) of the vapor in the inspired gas mixture. Usage follows a single, acute administration pattern for the duration of a surgical procedure, consisting of two phases: Induction and Maintenance.

For adults, the concentration used during the initial Induction phase typically ranges from 0.5% to 3% v/v, administered with oxygen or a mixture of oxygen and nitrous oxide. During the Maintenance phase, the concentration is continuously titrated to sustain the required depth of anesthesia, often falling between 0.5% and 1.5% v/v. The short duration of use is strictly limited to the time needed for the medical intervention.

Age-Specific Administration Rules

Concentration adjustments are utilized for specific populations. For instance, pediatric induction may require concentrations ranging from 1.5% to 2% v/v. Conversely, older adult patients generally require a reduced dose, with concentrations of 0.5% v/v or less often suitable for the maintenance phase of anesthesia.

Research Evidence / Overview of Studies for Фторотан (Halothane)

Evidence for Use in Induction and Maintenance of General Anesthesia

Halothane was studied for its primary role as a general anesthetic agent in Randomized Controlled Trials (RCTs) and comparative studies, largely conducted during the mid-to-late 20th century. These studies were used in research exploring the drug's role in creating a state of controlled unconsciousness for surgical procedures. Researchers examined several outcomes, including the induction time and physiological stability measures during the procedure.

Findings describe patterns observed in these studies, where research explored the goal of achieving the anesthetic state. Reported data for most studies were collected during the intraoperative and immediate postoperative phases. The data show patterns related to the duration of onset and recovery when compared to other agents that were included in the studies. Research contributes to the broader evidence landscape by providing context for how patients reported their experience with this agent.

Evidence in Special Populations

Halothane was studied for use in specific patient groups, particularly pediatric patients (infants and young children), and its properties were a subject of targeted investigation. Comparative trials applied in studies examining the speed and smoothness of induction in children. Research also describes that comparative studies monitored differences in physiological stability between children receiving Halothane and those receiving certain other agents. Data for these groups remain insufficient to provide complete, long-term context compared to the extensive data accumulated for newer compounds.

What is Still Uncertain About Фторотан Research

A number of research limitations exist regarding the current evidence base for Halothane. The available data is largely historical, and the clinical standards against which it was measured are no longer the same. The long-term effects are not fully established in large, prospective trials, and the evidence quality varies across the older observational studies that explored extended outcomes. Researchers and reviewers note that subgroup findings are uncertain for specific, modern, comorbidity-defined patient populations. Findings describe group patterns, not personal outcomes, and the evidence highlights what is known—and what is still uncertain—about this agent.

Common questions about Фторотан (FAQ)

---

Q: If I am pregnant, is it safe for my unborn baby if I receive Halothane?

Regulatory documents indicate that use of Halothane during pregnancy is generally not recommended, especially during early gestation. Safety regarding effects on fetal development is not established according to official product information. Its use is also not recommended for obstetrical anesthesia unless a specific requirement for uterine relaxation is present during the procedure.

Q: How long does it take to fully recover from Halothane anesthesia?

Studies summarized in regulatory context have collected data on the duration of onset and recovery from Halothane anesthesia. These findings describe patterns related to the duration of onset and recovery when compared to other agents that were included in those studies, providing context on the expected length of the post-anesthesia phase.

Q: What is the highest risk of using Halothane?

The official safety profile highlights specific serious, though rare, adverse reactions. These include Malignant Hyperthermia (MH), a potentially fatal hypermetabolic state, and severe Halothane-induced Hepatitis, which may lead to acute liver failure. The profile also notes an increased risk of severe liver injury associated with repeated exposures to the agent.

Q: Is it OK to use this drug if I have an existing liver condition?

Regulatory criteria state that use is absolutely contraindicated (prohibited) if a patient has a prior unexplained fever, jaundice, or severe liver dysfunction following a previous exposure to Halothane or similar agents. Special caution is also officially required for patients who have any pre-existing liver disease.

Q: Can I drink alcohol before or after receiving Фторотан?

Official information notes that alcohol consumption may be a risk factor that increases the potential for adverse hepatic (liver) effects. This is primarily due to shared metabolic pathways between alcohol and the anesthetic. Official information does not provide guidance on pre- or post-procedure alcohol consumption; however, a clinician would typically review this as part of the anesthetic pre-assessment.

Q: Is Halothane used for pain management or is it only for general anesthesia?

The drug’s official function is strictly for the induction and maintenance of general anesthesia. This process is intended to create a controlled state of unconsciousness, amnesia, and complete sensory block. While this state includes a block of sensory input, its primary clinical indication is general anesthesia, not stand-alone pain relief (analgesia).

Q: Why is there thymol added to the liquid in the bottle?

According to the official product information, a small concentration of thymol (typically 0.01%) is added to the volatile liquid. The purpose of the thymol is to act as a stabilizer. This ingredient helps prevent the chemical degradation and breakdown of the anesthetic product during its storage.

How to Store and Dispose of Фторотан (Halothane)

The official labeling for Halothane specifies mandatory storage conditions due to the product's chemical sensitivity.

---

Storage Requirements

• Light Protection: Halothane must be protected from light and stored in its original, typically amber colored bottles.
• Container: The container must be tightly closed to prevent evaporation, and the liquid must contain 0.01% thymol as a stabilizer.
• Child Safety: Like all medicines, it must be stored out of the sight and reach of children.
• Vaporizer Handling: Vaporizers should be emptied at the end of each operating day. If the liquid becomes yellow colored from thymol accumulation, it must be discarded as it indicates instability.

---

Disposal Instructions

Any discolored or unused product must be discarded. Disposal of all waste material must be carried out in accordance with local requirements for pharmaceutical waste.